AVLSA
COGT icon

Atlas Venture Life Science Advisors’s Cogent Biosciences COGT Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-186,487
Closed -$1.4M – 17
2022
Q1 		$1.4M Sell
186,487
-36,489
-16% -$254K 0.18% 17
2021
Q4 		$1.91M Buy
+222,976
New +$1.94M 0.18% 15

Other funds holding COGT

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Atlas Venture Life Science Advisors's COGT Position: Q2 2022 in Review

Atlas Venture Life Science Advisors sold out of Cogent Biosciences (COGT) in Q2 2022, closing a stake of 186,487 shares — an estimated $1.4M sold.

Atlas Venture Life Science Advisors first reported a position in COGT in Q4 2021 and held it in 2 quarters. The position peaked at $1.91M in Q4 2021. 112 funds tracked by Wall St. Rank hold COGT as of Q2 2022.

  • Atlas Venture Life Science Advisors reported no remaining Cogent Biosciences position as of Q2 2022 after selling out during the quarter.
  • Atlas Venture Life Science Advisors sold 186,487 Cogent Biosciences shares in Q2 2022, an estimated $1.4M.
  • Atlas Venture Life Science Advisors first reported a position in Cogent Biosciences in Q4 2021 and held it in 2 quarters.
  • Atlas Venture Life Science Advisors's Cogent Biosciences position peaked at $1.91M in Q4 2021.
  • 112 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2022.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2022, filed 3 Aug 2022.